DataMEDS AI Q3 Revenue Jumps 50% Sequential, Net Profit $10.5M

DataMEDS AI, Inc. (NASDAQ: MEDS) reported third-quarter 2026 revenue of $2.7 million on Monday, a 50% sequential increase from $1.8 million in the second quarter, and net income of $10.535 million, or $2.72 per diluted share, the company announced. The Tampa-based healthcare firm, which operates the Corexa Pharmacy and the EinsteinRx AI platform, also said it regained full compliance with Nasdaq listing standards on October 19, 2026, including the net equity requirement.

Context — Why DataMEDS AI's Q3 2026 Results Matter Now

The sequential revenue jump arrives as DataMEDS rebuilds its operating profile following a turbulent 2025. In the third quarter of 2025, the company reported a net operating loss of $34.318 million and a loss of $23.07 per share on 1.488 million weighted average shares. The swing to a $10.535 million profit in Q3 2026 is largely attributable to a $19.065 million gain on extinguishment of debt and outstanding liabilities tied to prior management litigation, alongside reduced management compensation and lower general and administrative expenses.

The company's gross profit for Q3 2026 was $431,880 on $2.669 million in net revenues, translating to a gross margin of roughly 16.2%. That compares with gross profit of $231,012 on $3.013 million in the year-earlier quarter, when the gross margin was about 7.7%. The improvement in margin, despite lower absolute revenue year over year, reflects a shift in revenue mix toward higher-margin pharmacy dispensing.

Management tied the sequential revenue growth to Corexa Pharmacy drug dispensing. "Corexa Pharmacy drove a 50% sequential increase in revenue this quarter with continued growth expected for the fourth quarter," said Gerald Commissiong, Interim Co-CEO of DataMEDS. The company said it expects continued growth based on added revenue streams from medical foods and diagnostic lab tests.

For context on the broader healthcare sector, the report provides no peer comparison or index benchmark. What the report does supply is the company's own sequential and year-over-year figures, which show a business in transition: top-line revenue remains below 2025 levels on a nine-month basis, but the cost structure has shrunk dramatically.

Data — What the Numbers Show

Nine-month 2026 net revenues were $6.008 million, down from $21.667 million in the first nine months of 2025. Cost of net revenues fell to $5.224 million from $20.238 million over the same period. Total operating expenses for the nine months ended September 30, 2026 were $17.519 million, versus $69.826 million a year earlier, a reduction of roughly 75%.

Metric	Q3 2026	Q3 2025
Net revenues	$2,668,980	$3,012,904
Gross profit	$431,880	$231,012
Net income (loss)	$10,535,560	$(34,318,204)
Diluted EPS	$2.72	$(23.07)
Weighted avg diluted shares	3,961,210	1,487,588

The balance sheet shows cash and cash equivalents of $476,598 as of September 30, 2026, up from $42,571 at December 31, 2025. Total assets rose to $38.734 million from $30.459 million. Total liabilities declined to $38.562 million from $42.907 million. Stockholders' equity flipped to a positive $171,695 from a deficit of $12.448 million at year-end 2025.

Goodwill increased to $15.787 million from $14.194 million, and other intangible assets, net, rose to $13.249 million from $10.315 million, reflecting the September 2026 acquisition of Helomics Corporation. Convertible notes payable, net of discount, stood at $15.276 million as of September 30, 2026, up from zero at December 31, 2025.

Analysis — What It Means for Markets and Sectors

The headline profit is not an operating profit. The $10.535 million net income includes a $19.065 million gain on debt extinguishment and a $703,014 other income item, against a $3.374 million loss from operations. Strip out those non-operating items and the quarter still shows an operating loss. Investors screening MEDS on net income alone would misread the quality of earnings.

The strategic pivot toward GLP-1 medications is the company's core narrative. DataMEDS launched the Health Lives Here mobile app with NFL Alumni Health as a marketing partner, giving Corexa Pharmacy a direct channel to dispense FDA-approved GLP-1 drugs and Forzet, a medical food for muscle loss associated with weight loss therapies. In October 2026, the company obtained an exclusive license to the REBOOT GLP-1 patient management platform.

A counter-argument worth weighing: the HMO relationship is a non-binding memorandum of understanding with a Florida-based HMO covering 25,000+ members. Definitive agreements are expected in Q4 2026, but there is no guarantee they will be executed. The compounded peptides launch under FDA's Enforcement Discretion Policy carries regulatory risk, and the company notes compounded drugs are not FDA-approved.

The Helomics acquisition adds a CLIA-certified cancer diagnostics laboratory and a biobank of 70,000+ primary tumor biopsies. Humana's South Carolina Medicaid coverage policy for the ChemoFx Assay, effective July 22, 2026, adds a proprietary revenue stream. Together, these moves position MEDS in the GLP-1 and diagnostics supply chain, sectors where pharmacy benefit managers and telehealth platforms compete for patient share.

Outlook — What to Watch Next

The company said it expects continued revenue growth in the fourth quarter of 2026, citing medical foods and diagnostic lab tests as incremental contributors. Definitive HMO agreements are expected in Q4 2026. The REBOOT license and compounded peptides launch are recent, so their revenue contribution will first appear in Q4 or Q1 2027 results.

Key items to monitor: whether Corexa Pharmacy dispensing revenue sustains its sequential growth rate; whether the HMO MOU converts to a binding contract; and whether Helomics grows ChemoFx testing volumes and reimbursement. The company did not disclose revenue targets or guidance figures for Q4 2026.

On the balance sheet, the convertible notes payable of $15.276 million and accounts payable of $13.062 million remain significant relative to cash of $476,598. Liquidity and the ability to fund operations are listed among the company's own risk factors. Nasdaq compliance was regained on October 19, 2026, but maintaining the net equity requirement depends on continued equity improvement.

Frequently Asked Questions

What does DataMEDS AI's Q3 2026 profit mean for retail investors?

The $10.535 million net income is driven primarily by a $19.065 million non-cash gain on debt extinguishment, not by operating earnings. The company still posted a $3.374 million loss from operations. Retail investors should distinguish between accounting profit from liability settlements and cash-generating operating profit, which has not yet been achieved.

Why did DataMEDS AI revenue fall year over year but rise sequentially?

Q3 2026 revenue of $2.669 million was below Q3 2025's $3.013 million, but up 50% from Q2 2026's $1.8 million. The sequential gain came from Corexa Pharmacy drug dispensing. The year-over-year decline reflects a smaller revenue base after prior business changes. The company expects Q4 2026 growth from medical foods and lab tests.

What happens next for MEDS stock after Nasdaq compliance?

Regaining Nasdaq listing compliance on October 19, 2026 removes the immediate delisting risk, including the net equity requirement. The next catalysts are Q4 2026 results, the HMO definitive agreement expected in Q4, and initial revenue from the REBOOT license and compounded peptides. The company did not provide specific financial guidance.

Bottom Line

DataMEDS AI's Q3 profit came from debt extinguishment, not operations, leaving the Corexa GLP-1 growth story unproven on cash earnings.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.